Dr Yves Fradet graduated from Laval University (Quebec, Canada) in 1981 and completed an oncology fellowship at the Memorial Sloan-Kettering Cancer Center, with Drs Willet Whitmore and Lloyd Old. In 1983 he founded, at the Laval University Cancer Research Center, a translational and clinical research laboratory  in urological cancers whose work are supported continuously for more than 30 years.

Dr Fradet still has a very active practice in uro-Oncology within the Urologic Oncology Section and the Urology Service at the CHU de Québec- Hôtel-Dieu de Québec where he has grouped a team of specialists among the most important in Canada including seven uro-oncologists, three of which are also holders of PhD.

He is a member of many national and international societies, including since 2001, the American Association of Genitourinary Surgeons in which he was invited to be part of the 75 members in America. More recently, he was appointed international honorary member of the Association of Academic European Urology, membership awarded to those who have had important influence on urology. Dr Fradet is often invited as a guest speaker at national and international meetings, as a visiting professor, and as a consultant to many organizations. He was the founding chairman of the Canadian Urologic Oncology Group from 1988 to 1995 and chairman of the Department of Surgery at Laval University from 2000 to 2008. He has authored over 330 publications and book chapters and more than 600 abstracts.

Hôpital de l'Enfant-Jésus
1401, 18e rue
G4.610
Québec, QC
Canada G1J 1Z4
+1 418-525-4444, extension 67694
+1 418-691-3154
Yves.Fradet@crchudequebec...

Latest news

345 entries « ‹ 34 of 35 › »

Fradet Y, Cordon-Cardo C, Whitmore Jr, Melamed MR, Old LJ

Cell surface antigens of human bladder tumors: definition of tumor subsets by monoclonal antibodies and correlation with growth characteristics

Journal Article

Cancer Res, 46 (10), 1986.

Abstract | Links:

Fradet Y, Laverdiere J, Beaudoin L

[The treatment of localized cancer of the prostate using radioactive iodine implants]

Journal Article

Union Med Can, 114 (9), 1985.

| Links:

Fradet Y, Tardif M, Parent-Vaugeois C

[The use of multiparameter flow cytometry in the detection and evaluation of human bladder tumors]

Journal Article

Union Med Can, 114 (9), 1985.

| Links:

Huffman JL, Fradet Y, Cordon-Cardo C, Herr HW, Pinsky CM, Oettgen HF, Old LJ, Whitmore Jr, Melamed MR

Effect of intravesical Bacillus Calmette-Guérin on detection of a urothelial differentiation antigen in exfoliated cells of carcinoma in situ of the human urinary bladder

Journal Article

Cancer Res, 45 (10), 1985.

Abstract | Links:

Fradet Y, Cordon-Cardo C, Thomson T, Daly ME, Whitmore Jr, Lloyd KO, Melamed MR, Old LJ

Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies

Journal Article

Proc Natl Acad Sci U S A, 81 (1), 1984.

Abstract | Links:

Cordon-Cardo C, Bander NH, Fradet Y, Finstad CL, Whitmore WF, Lloyd KO, Oettgen HF, Melamed MR, Old LJ

Immunoanatomic dissection of the human urinary tract by monoclonal antibodies

Journal Article

J Histochem Cytochem, 32 (10), 1984.

Abstract | Links:

Fradet Y, Roy R, Lachance JG, Noël R

Kidney graft survival: role of blood transfusions and lymphocytotoxic antibodies

Journal Article

Clin Nephrol, 18 (2), 1982.

Abstract | Links:

Roy R, Lachance JG, Fradet Y, Hebert J

Characterization of lymphocytotoxic antibodies in renal transplantation

Journal Article

Transplantation, 31 (1), 1981.

Abstract | Links:

Roy R, Fradet Y, Lachance JG

Influence of HLA-A and HLA-B cross-reactive antigen matching on kidney graft survival

Journal Article

Tissue Antigens, 18 (2), 1981.

Abstract | Links:

Fradet Y, Simard J, Grose JH, Lebel M

Enhanced urinary prostaglandin E2 in postobstructive diuresis in humans

Journal Article

Prostaglandins Med, 5 (1), 1980.

| Links:

345 entries « ‹ 34 of 35 › »
Signaler des ajouts ou des modifications

Active projects

  • En route towards prebiotic clinical trials for enhancement of immunotherapies in bladder and prostate cancers, from 2020-06-01 to 2024-04-30
  • Repurposing bicalutamide to improve the response to immune checkpoint inhibition for treatment of advanced urothelial carcinoma, from 2022-08-01 to 2026-07-31
  • Targeting sex steroids to improve the response to bladder cancer immunotherapy, from 2021-10-01 to 2026-09-30
  • What are my options? A feasibility study of a personalized primary prevention strategy for women and men at high risk of breast and prostate cancer, from 2022-01-15 to 2024-01-14

Recently finished projects

  • CQDM_Projet de recherche PICT-01 sur le cancer de la prostate , from 2019-12-01 to 2022-11-30
  • Developement of a prostate cancer vaccine, from 2022-07-20 to 2023-07-19
  • Impact of lifestyle on gut barrier function, bacterial translocation and risk of prostate cancer, from 2020-09-01 to 2023-04-30
  • Intégration de l'imagerie par résonance magnétique multiparamétrique dans la trajectoire diagnostique des patients avec suspicion de cancer de la prostate au CHU de Québec - Université Laval , from 2020-06-15 to 2022-09-30
  • Interaction between environment, diet, physical activities, and sexual habits, in the risk of prostate cancer. Validation of biomarkers to personnalize preventive interventions., from 2012-10-01 to 2021-12-31
  • Maintien de colonies de souris transgéniques exprimant des molécules de CMH humaines , from 2022-03-22 to 2023-03-21
  • Stromal Gene Expression Predicts And May Drive Metastasis in Prostate Cancer, from 2017-04-01 to 2022-03-31
  • Testing of Biological Activity of DPX-Survivac in vivo in HLA-A1, HLA-A24 and HLA-B7 Transgenic mice, from 2021-05-28 to 2021-11-27
Data provided by the Université Laval research projects registery